2021 Summer Meeting – Manchester

18th July 2021 – 21st July 2021
University of Manchester

2021 Call for Symposium Proposals

The annual summer meeting is the showcase event of the BAP year. To ensure that the meeting is successful we need to provide a programme that is topical, well balanced and reflects the needs and interests of our Members. The best way this can be achieved is to have substantial input from the membership. With the programme for the 2020 Meeting now in place (19-22 July in London), we are looking towards the 2021 Meeting, which will be held in Manchester from 18-21 July.

We encourage all BAP Members to think about the topics that they would like to see in the summer meeting programme, and to put forward symposium proposals for consideration by Council. There are several factors that Council uses to assess proposals and which are important to consider when choosing the topic and content of symposia, including:

  • quality of the scientific information presented and the speakers (four in total)
  • topical nature of the subject
  • breadth of interest
  • relevance to, and inclusion of, clinical and nonclinical psychopharmacology; in particular we encourage symposia that include translational elements
  • lack of overlap with, or repetition of, recent BAP symposia (see below)
  • geographical/institutional balance
  • the balance of symposium speakers/chairs which should reflect the BAP's statement on equality and diversity

BAP is able to provide the following for a maximum of four speakers/chairs:

  • Registration for the whole Summer Meeting
  • One nights’ accommodation
  • A ticket for the Gala Dinner
  • A contribution towards travel expenses:- £100 max for UK / £200 max for Europe / £500 max for RoW

Members of Council welcome discussion of ideas, whether tentative or clearly formulated.

Proposals for symposia for the 2021 Summer Meeting – to be held at the Renold Building, University of Manchester from Sunday 18 to Wednesday 21 July – should be submitted via the button below by no later than 15 May 2020, and will be discussed by the BAP Council at their July meeting.

Propose a Symposium

Previous Symposia


  • Non-invasive neurostimulation treatments from first episode to treatment-resistant depression: clinical efficacy and mechanisms of action
  • Big data approaches to understanding mental disorders and treatment response
  • Chronic Fatigue Syndrome – Biological determinants and pathways to treatment
  • Mapping impulsivity and compulsivity: phenotypes, cognitive markers, neural domains and treatment
  • Enabling translational psychopharmacology through preclinical MR technology
  • Does research on body-brain interactions hold promise for the development of novel treatments for addiction and eating disorders?
  • What can computational analyses of brain imaging data tell us about mechanisms in psychiatric disorders?
  • Social neuropeptides: Central oxytocin and vasopressin pathways and translational implications
  • Cognitive impairment in mood disorders - a forgotten pharmacological target?


  • What happened to the promise of imaging biomarkers for major depressive disorder? New opportunities and challenges for drug development
  • Human induced-pluripotent stem cell technology for modelling psychiatric disorders – promises, pitfalls and new directions
  • Early adversities and trajectories to adult psychopathology
  • Drugs and the adolescent brain: recent advances
  • From neuro-receptor binding to brain function: translational value of multimodal approaches in psychopharmacology
  • The complement system and inflammation as targets in neuropsychiatric disorders
  • What do computational models tell us about cognition in depression and psychosis?
  • The orexinergic system of the brain and its importance for neuropsychiatry
  • Novel therapeutic uses of cannabinoids


  • Early intervention for the next generation: Therapeutic challenges in youth mental health
  • Towards a mechanistic understanding of anxiety disorders: translational, pharmacological, neural and computational perspectives
  • PTSD; Exposure to traumatic events, brain changes and current and novel treatments
  • Microglia role in neuropsychiatric disease and its potential as a treatment target
  • New concepts in the co-morbidity of psychiatric disorders, eating disorders and obesity
  • Risk factors for autism and schizophrenia: Convergence or divergence?
  • The opiate system in addiction: latest findings from substance and behavioural addictions
  • Bridging the translational gap in psychiatry: a role for neuronal oscillations?
  • Mineralocorticoid/ glucocorticoid receptor imbalance and early life stress as risk factors for affective disorders


  • Personalized pharmacological treatments for depression: Will big data achieve what clinicians can't?
  • The psychopharmacology of emerging calcium channel targets
  • Behavioural and substance addictions: Similarities and differences
  • Adverse and beneficial effects of cannabinoids - new insights from genetics and clinical trials
  • The role of brain connectivity in brain disorders and their treatment
  • Psychopharmacology of the older and, almost certainly, degenerating brain
  • Treatment of dysfunction in hot and cold cognition in mood disorders
  • The brain-gut axis: Breaking the dichotomy between physical and mental health
  • Biomarkers of treatment response for schizophrenia and bipolar affective disorder: Latest updates


  • New paradigms and treatment approaches in schizophrenia
  • New perspectives on functions of 5-HT sub-systems
  • Towards a gender specific psychopharmacology: the impact of neurosteroids, gonadal steroids and oxytocin
  • Bipolar disorder: progress on many fronts
  • Ketamine and addiction: promising treatment or probable cause?
  • Neuronal stem cells in mental health: will neurogenesis and iPS cells give us the antidepressants of the future?
  • Anhedonia, apathy, amotivation, anergia? Disrupted reward processing as a trans-diagnostic construct in mental illness
  • Dysfunctional neuro-immune system interactions in psychiatric disorders and their relevance for novel treatment strategies
  • Innovation in the treatment of obesity and binge eating


  • Use and abuse of novel psychoactive substances
  • Bipolar disorder: looking to the future
  • Of models and men: translational imaging studies in advancing mechanistic understanding of neuropsychiatric diseases
  • Where now for glutamatergic strategies for schizophrenia?
  • Sleep and drugs in the 21st century
  • The Electronic cigarette: from basic pharmacology to smoking harm reduction and cessation
  • Advances in compulsivity: a trans-diagnostic perspective
  • The role of synaptic proteins in schizophrenia and related neurodevelopmental disorders
  • Non-invasive neurostimulation